Hydrocobamine (Hydroxocobalamin Chloride)

Hydrocobamine is indicated for several clinical situations where vitamin B12 replacement is required. It is commonly used in the following contexts:

• Treatment of documented vitamin B12 deficiency
• Management of pernicious anemia
• Antidotal therapy for acute cyanide poisoning
• Support in patients with malabsorption syndromes affecting cobalamin uptake
• Adjunctive therapy in certain metabolic disorders involving methylmalonyl‑CoA mutase deficiency

• Hydroxocobalamin chloride acts as a cofactor for the enzymes methionine synthase and methylmalonyl‑CoA mutase. By delivering cobalamin to these enzymatic pathways, it facilitates the conversion of homocysteine to methionine and the metabolism of odd‑chain fatty acids, thereby supporting DNA synthesis, myelin formation, and normal red blood cell production.

Adverse reactions to Hydrocobamine are generally uncommon but can occur. They are categorized as follows:

Common

• Mild pain or irritation at the injection site
• Transient flushing or warmth
• Low‑grade fever
• Headache
• Nausea

Serious

• Severe allergic reaction (anaphylaxis) with rash, swelling, or difficulty breathing
• Hypotension
• Acute hemolytic anemia in susceptible individuals
• Severe hypertension (rare)
• Cardiovascular collapse

Before using Hydrocobamine, consider the following safety points:

• Assess for known hypersensitivity to hydroxocobalamin or any component of the formulation.
• Use caution in patients with a history of severe allergic reactions.
• Monitor cardiovascular status in individuals with pre‑existing hypertension.
• Evaluate renal function, as impaired clearance may affect plasma levels.
• Pregnancy and lactation status are unknown; weigh potential benefits against risks.
• Ensure proper injection technique to minimize local tissue injury.

Hydrocobamine may interact with other agents. Consider these interaction categories:

Avoid

• Concurrent use of high‑dose nitrous oxide, which can inactivate vitamin B12 and reduce therapeutic effect.
• Intravenous administration of certain contrast agents that may bind cobalamin.

Use with caution

• Metformin, which may impair cobalamin absorption over long‑term use.
• Proton‑pump inhibitors or H2‑blockers that reduce gastric acidity and affect oral B12 absorption (relevant for overall B12 status).
• Anticonvulsants such as phenytoin or carbamazepine, which may increase B12 metabolism.
• Chemotherapeutic agents that affect rapidly dividing cells, potentially altering B12 requirements.